PRODUCT MONOGRAPH

FLECAINIDE

Flecainide Acetate Tablets USP

50 mg and 100 mg

ANTIARRHYTHMIC AGENT

AA PHARMA INC.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7

DATE OF REVISION:
July 1, 2010
PRODUCT MONOGRAPH

FLECAINIDE
Flecainide Acetate Tablets USP
50 mg and 100 mg

THERAPEUTIC CLASSIFICATION

Antiarrhythmic Agent

ACTIONS AND CLINICAL PHARMACOLOGY

Flecainide belongs to the membrane stabilizing group of antiarrhythmic agents; it has electrophysiologic effects characteristics of the 1C class of the modified Vaughan-Williams classification. It also possesses local anesthetic properties.

In single cell preparations from canine cardiac tissues (Purkinje fibers), flecainide decreased the rate of rise ($V_{\text{max}}$, Phase 0) of the action potential without greatly affecting its duration; the duration of the effective refractory period was lengthened and a small change was observed in the slope of Phase 4 depolarization. In ventricular muscle, some lengthening of the action potential duration has been observed.

In man, flecainide produces a dose-related decrease in intracardiac conduction in all parts of the heart with the greatest effect on the His-Purkinje system (H-V conduction). Effects upon atrioventricular (AV) nodal conduction time and intra-atrial conduction times, although present, are less pronounced than those on ventricular conduction velocity. Significant effects on refractory periods were observed only in the ventricle. Sinus node recovery times (corrected) following pacing and spontaneous cycle lengths are somewhat increased. This latter effect may become significant in patients with sinus node dysfunction (see WARNINGS). In patients with accessory AV connections, flecainide has been shown to depress both anterograde and retrograde conduction over the bypass tract.

**Hemodynamics**
Decreases in ejection fraction, consistent with a negative inotropic effect, have been observed after a single administration of 200 to 250 mg of flecainide; both increases and decreases in
ejection fraction have been encountered during multidose therapy in patients at usual therapeutic
doses (see WARNINGS).

During long-term clinical studies, some patients have developed congestive heart failure (CHF)
while taking flecainide (see WARNINGS and ADVERSE EFFECTS).

Flecainide does not usually alter heart rate, although bradycardia and tachycardia have been
reported. In clinical studies, systolic and diastolic blood pressures increased slightly during
therapy. A few patients have required changes in antihypertensive medication.

**Pharmacokinetics/Metabolism**

Following oral administration, flecainide is nearly completely absorbed with bioavailability
of 90 to 95%. Peak plasma levels are attained at about 3 hours in most individuals (range, 1 to
6 hours). Food and antacids do not affect absorption. Flecainide does not undergo any
consequential presystemic biotransformation.

The plasma half-life averages about 20 hours (range, 12 to 27 hours) after multiple oral doses in
patients with premature ventricular complexes and normal renal function; this is similar to that in
patients with CHF (mean, 19 hours), but it is moderately longer than for healthy subjects (mean,
14 hours). In patients with renal impairment the plasma half-life of flecainide is often prolonged
and ranges from about 14 to 190 hours. Flecainide elimination from plasma is somewhat slower
in healthy elderly subjects (t1/2=18 hours) than in young healthy subjects.

Steady-state plasma levels are reached within 3 to 5 days; once steady-state is attained, no
additional drug accumulation in plasma occurs. Therapeutic plasma concentrations of flecainide
range from 0.2 to 1.0 µg/mL. The plasma levels are not directly proportional to dose. Within
the usual therapeutic dose range, plasma levels deviate upwards from direct proportionality
(average deviation about 10 to 15% per 100 mg).

The extent of flecainide binding to plasma proteins is about 40% and is independent of plasma drug
level over the range of 0.015 to 3.4 µg/mL.

In healthy subjects, about 30% of a single oral dose (range, 10% to 50%) is excreted in urine as
unchanged flecainide. The 2 major metabolites are meta-o-dealkylated flecainide (active, but about
one fifth as potent) and the meta-o-dealkylated lactam of flecainide (nonactive metabolite). These
two metabolites (primarily conjugated) account for most of the remaining portion of the dose in
urine. Several minor metabolites (3% of the dose or less) are also found in urine; only 5% of an oral
dose is excreted in feces. In patients, free (unconjugated) plasma levels of the two major metabolites are very low (less than 0.05 µg/mL).

With increasing renal impairment, the extent of unchanged drug excretion in urine is reduced. Since flecainide is also extensively metabolized, there is no simple relationship between creatinine clearance and the rate of flecainide elimination from plasma (see DOSAGE AND ADMINISTRATION). When urine is very alkaline (pH 8 or higher), as may occur in rare conditions (e.g., renal tubular acidosis, strict vegetarian diet), flecainide elimination from plasma is much slower.

Hemodialysis removes only about 1% of an oral dose as unchanged flecainide.

**Comparative Bioavailability**

A comparative, randomized, single-dose, 2-way crossover fasted study of FLECAINIDE 100 mg Tablets manufactured by AA Pharma Inc. and Tambocor™ 100 mg Tablets manufactured by 3M Pharmaceuticals was conducted. The mean pharmacokinetic parameters of the 20 subjects who completed the study are listed below.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Geometric Mean Arithmetic Mean (CV%)</th>
<th>Ratio of Geometric Means (%)**</th>
<th>95% Confidence Interval (%)**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FLECAINIDE</td>
<td>Tambocor™†</td>
<td></td>
</tr>
<tr>
<td>AUCₚ (ng·h/mL)</td>
<td>2216 (2322 (30)</td>
<td>2176 (2264 (26)</td>
<td>101.8</td>
</tr>
<tr>
<td>AUC₁ (ng·h/mL)</td>
<td>2250 (2360 (31)</td>
<td>2208 (2298 (26)</td>
<td>101.9</td>
</tr>
<tr>
<td>Cₚₚₛ (ng/mL)</td>
<td>145 (148 (21)</td>
<td>148 (152 (22)</td>
<td>98.1</td>
</tr>
<tr>
<td>Tₚₚₛ* (h)</td>
<td>3.43 (33)</td>
<td>3.19 (21)</td>
<td>-</td>
</tr>
<tr>
<td>Tₜₚₛ* (h)</td>
<td>11.2 (18)</td>
<td>11.0 (17)</td>
<td>-</td>
</tr>
</tbody>
</table>

* Arithmetic means (CV%).

**Based on the least squares estimate.

† Tambocor™ (marketed by 3M Pharmaceuticals, 3M Canada Inc. (London, ON, Canada)) was purchased in Canada.
In addition, a comparative, randomized, single-dose, 2-way crossover fed study of FLECAINIDE 100 mg Tablets manufactured by AA Pharma Inc. and Tambocor™ 100 mg Tablets manufactured by 3M Pharmaceuticals was conducted. The mean pharmacokinetic parameters of the 18 subjects who completed the study are listed below.

### Summary Table of the Comparative Bioavailability Data
**Flecainide (Dose: 1 x 100 mg) from Measured Data - Under Fed Conditions**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Geometric Mean</th>
<th>Arithmetic Mean (CV%)</th>
<th>Ratio of Geometric Means (%)**</th>
<th>95% Confidence Interval (%)**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FLECAINIDE</td>
<td>Tambocor™†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUCₜ (ng·h/mL)</td>
<td>2446</td>
<td>2508 (25)</td>
<td>2494</td>
<td>2562 (25)</td>
</tr>
<tr>
<td>AUCᵢ (ng·h/mL)</td>
<td>2521</td>
<td>2597 (28)</td>
<td>2567</td>
<td>2647 (27)</td>
</tr>
<tr>
<td>Cₑₚax (ng/mL)</td>
<td>138 (16)</td>
<td>141</td>
<td>143</td>
<td>140 (16)</td>
</tr>
<tr>
<td>Tₑₚmax* (h)</td>
<td>3.36 (40)</td>
<td>2.94 (38)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>T₁/₂ (h)</td>
<td>13.5 (28)</td>
<td>13.4 (20)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* Arithmetic means (CV%).
**Based on the least squares estimate.
† Tambocor™ (marketed by 3M Pharmaceuticals, 3M Canada Inc. (London, ON, Canada)) was purchased in Canada.

### INDICATIONS AND CLINICAL USE

No antiarrhythmic drug has been shown to reduce the incidence of sudden death in patients with asymptomatic ventricular arrhythmias. Most antiarrhythmic drugs have the potential to cause dangerous arrhythmias; some have been shown to be associated with an increased incidence of sudden death. In light of the above, physicians should carefully consider the risks and benefits of antiarrhythmic therapy for all patients with ventricular arrhythmias.

In patients without structural heart disease and with disabling symptoms, FLECAINIDE (Flecainide Acetate) Tablets USP is indicated for the prevention of:
• paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism,
• paroxysmal atrial fibrillation/flutter (PAF).

Patients treated with FLECAINIDE for supraventricular arrhythmias having impaired left ventricular function (ejection fraction <40) and/or ischemic heart disease may be at increased risk for cardiac adverse reactions. Use of FLECAINIDE in chronic atrial fibrillation has not been adequately studied and is not recommended (see boxed WARNINGS).

FLECAINIDE is also indicated for the treatment of:
• documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are life-threatening.

Because of the proarrhythmic effects of FLECAINIDE, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. The use of FLECAINIDE is not recommended in patients with less severe ventricular arrhythmias, even if the patients are symptomatic (see WARNINGS). Use of FLECAINIDE for treatment of sustained ventricular tachycardia should be initiated in the hospital.

FLECAINIDE should not be used in patients with recent myocardial infarction (see boxed WARNINGS).

**CONTRAINDICATIONS**

FLECAINIDE (Flecainide Acetate) Tablets USP is contraindicated in patients with:

• Second- or third-degree AV block, unless a pacemaker is present to sustain rhythm; bifascicular or trifascicular bundle branch block unless a pacemaker is present to sustain rhythm; cardiogenic shock, or known hypersensitivity to the drug.
WARNINGS

Mortality: The results of the Cardiac Arrhythmia Suppression Trial (CAST) in post-myocardial infarction patients with asymptomatic ventricular arrhythmias showed a significant increase in mortality and in non-fatal cardiac arrest rate in patients treated with encainide or flecainide compared with a matched placebo-treated group. This rate was 19/323 (5.8%) for flecainide and 7/318 (2.2%) for its matched placebo. The average duration of treatment with flecainide was 10 months. CAST was continued using a revised protocol with the moricizine and placebo arms only. The trial was prematurely terminated because of a trend towards an increase in mortality in the moricizine treated group.

The applicability of these results to other populations or other antiarrhythmic agents is uncertain, but at present it is prudent to consider these results when using any antiarrhythmic agent.

Ventricular Pro-arrhythmic Effects in Patients with Atrial Fibrillation/Flutter: A review of the world literature revealed reports of 568 patients treated with oral flecainide for paroxysmal atrial fibrillation/flutter (PAF). Ventricular tachycardia was experienced in 0.4% (2/568) of these patients. Of 19 patients in the literature with chronic atrial fibrillation, 10.5% (2/19) experienced ventricular tachycardia or ventricular fibrillation. FLECAINIDE IS NOT RECOMMENDED FOR USE IN PATIENTS WITH CHRONIC ATRIAL FIBRILLATION. Case reports of ventricular proarrhythmic effects in patients treated with flecainide for atrial fibrillation/flutter have included increased premature ventricular contractions (PVCs), ventricular tachycardia (VT), ventricular fibrillation (VF), and death.

As with other class I agents, patients treated with flecainide for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing of the atrial rate. A paradoxical increase in the ventricular rate also may occur in patients with atrial fibrillation who receive flecainide. Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication.
**Proarrhythmic Effects**

Flecainide, like other antiarrhythmic agents, can cause new or worsened supraventricular or ventricular arrhythmias. Ventricular proarrhythmic effects range from an increase in frequency of PVCs to the development of more severe ventricular tachycardia (e.g., tachycardia that is more sustained or more resistant to conversion to sinus rhythm), with potentially fatal consequences.

In studies of 225 patients with supraventricular arrhythmia (108 with paroxysmal supraventricular tachycardia and 117 with paroxysmal atrial fibrillation), there were nine (4%) proarrhythmic events, eight of them in patients with paroxysmal atrial fibrillation. Of the nine, seven (including the one in a PSVT patient) were exacerbations of supraventricular arrhythmias (longer duration, more rapid rate, harder to reverse). Two were ventricular arrhythmias, including one fatal case of VT/VF and one wide complex VT (the patient showed inducible VT, however, after withdrawal of flecainide), both in patients with paroxysmal atrial fibrillation and known coronary artery disease.

In studies of patients with ventricular arrhythmias, flecainide proarrhythmic effects were reported in 6.8% of patients. Three fourths of the proarrhythmic events were new or worsened ventricular tachyarrhythmias, the remainder being increased frequency of PVCs or new supraventricular arrhythmias.

In patients with complex ventricular arrhythmias, it is often difficult to distinguish a spontaneous variation in the patient's underlying rhythm disorder from drug-induced worsening, so that the following occurrence rates must be considered approximations. Their frequency appears to be related to dose and to the underlying cardiac disease. Among patients treated for sustained VT (who frequently also had heart failure, a low ejection fraction, a history of myocardial infarction and/or an episode of cardiac arrest), the incidence of proarrhythmic events was 13% when dosage was initiated at 200 mg/day with slow upward titration, and did not exceed 300 mg/day in most patients. In early studies in patients with sustained VT utilizing a higher initial dose (400 mg/day) the incidence of proarrhythmic events was 26%; moreover, in about 10% of the patients treated, proarrhythmic events resulted in death, despite prompt medical attention. With lower initial doses, the incidence of proarrhythmic events resulting in death decreased to 0.5% of these patients. Accordingly, it is extremely important to follow the recommended dosage schedule (see DOSAGE AND ADMINISTRATION).
The relatively high frequency of proarrhythmic events in patients with sustained ventricular tachycardia and serious underlying heart disease, and the need for careful titration and monitoring, requires that therapy of patients with sustained VT be started in the hospital (see DOSAGE AND ADMINISTRATION).

**Heart Failure**

Because flecainide has a negative inotropic effect, it may cause or worsen congestive heart failure (CHF), particularly in patients with cardiomyopathy, pre-existing severe heart failure (NYHA functional class III or IV) or low ejection fractions (less than 40%). In patients with supraventricular arrhythmias new or worsened CHF developed in 0.4% (1/225) of patients. New or worsened CHF in ventricular patients, which might be attributed to treatment with flecainide occurred in approximately 5% of patients studied in various trials. CHF developed rarely (1%) in patients who had no previous history of CHF. Flecainide should be used cautiously in patients who are known to have a history of CHF or myocardial dysfunction. The initial dose should be no more than 100 mg bid in such patients (see DOSAGE AND ADMINISTRATION) and they should be carefully monitored. Careful attention must be given to maintenance of cardiac function, including optimization of digitalis, diuretic or other therapy. In the cases where CHF has occurred or worsened during flecainide therapy, the onset has ranged from a few hours to several months after starting therapy. Patients who develop evidence of reduced myocardial function while on flecainide should have their dose reduced or discontinued. It is recommended that plasma flecainide levels be monitored. Attempts should be made to keep trough plasma levels below 0.7 to 1.0 µg/mL.

**Effects on Cardiac Conduction**

In most patients flecainide slows cardiac conduction sufficiently to produce dose-related increases in the duration of the PR, QRS and QT intervals on the electrocardiogram.

PR interval increases on average about 25% (0.04 seconds) and as much as 118% in some patients. Approximately one-third of patients may develop new first degree AV heart block (PR interval 0.20 seconds). The QRS complex increases on average about 25% (0.02 seconds) and as much as 150% in some patients. Many patient develop QRS complexes with a duration of 0.12 seconds or more. In one study, 4% of patients developed new bundle branch block while on flecainide. The degree of lengthening of PR and QRS intervals does not predict either efficacy or the development of cardiac adverse effects. In clinical trials, it was unusual for PR intervals to increase to 0.30 seconds or more, or for QRS intervals to increase to 0.18 seconds or more.
Thus, caution should be used when such intervals occur, and dose reductions may be considered. The QT interval widens about 8%, but most of this widening (about 60% to 90%) is due to widening of the QRS duration. The JT interval (QT minus QRS) only widens about 4% on the average. Significant JT prolongation occurs in less than 2% of patients. There have been a few cases of Torsade de Pointes-type arrhythmia associated with flecainide-induced QT prolongation and bradycardia.

Clinically significant conduction changes have been observed with these incidences: sinus node dysfunction such as sinus pause, sinus arrest and symptomatic bradycardia (1.2%); second-degree AV block (0.5%); and third-degree AV block (0.4%). An attempt should be made to manage the patient on the lowest effective dose in an effort to minimize these effects (see DOSAGE AND ADMINISTRATION). If second- or third-degree AV block, or right bundle branch block associated with a left hemiblock occurs, flecainide therapy should be discontinued unless a temporary or implanted ventricular pacemaker is in place to ensure an adequate ventricular rate.

**Sinus Node Dysfunction**
In patients with sinus node dysfunction (e.g., sick sinus syndrome), flecainide should be used with extreme caution because it may cause sinus bradycardia, sinus pause or sinus arrest.

**Digitalis Intoxication**
Flecainide has not been evaluated in the treatment of arrhythmias secondary to digitalis intoxication, and it increases the plasma level of digoxin. Therefore, it is not recommended for such use.

**Electrolyte Disturbances**
The presence of potassium excess or deficit may alter the effects of antiarrhythmic drugs. Any pre-exisiting hypokalemia or hyperkalemia should be corrected before administration of flecainide.

**Effects on Pacemaker Thresholds**
Flecainide is known to increase endocardial pacing thresholds and may suppress ventricular escape rhythms. These effects are reversible if flecainide is discontinued. It should be used with caution in patients with permanent pacemakers or temporary pacing electrodes and should not be administered to patients with existing poor thresholds or nonprogrammable pacemakers unless suitable pacing rescue is available.
The pacing threshold in patients with pacemakers should be determined prior to instituting therapy with flecainide, again after one week of administration and at regular intervals thereafter. Generally, threshold changes are within the range of multiprogrammable pacemakers and, when these occur, a doubling of either voltage or pulse width is usually sufficient to regain capture.

**Concomitant Antiarrhythmic Therapy**
Due to limited exposure, the concomitant use of flecainide and other antiarrhythmic agents is not recommended.

Both disopyramide and verapamil have negative inotropic properties and the effects of giving them with flecainide are unknown. Therefore, neither disopyramide nor verapamil should be administered concurrently with flecainide unless, in the judgment of the physician, the possible benefit of this combination therapy clearly outweighs the risks.

When flecainide and amiodarone are coadministered, plasma flecainide levels may increase two-fold or more. If the combination therapy is required, the dose should be reduced (see DOSAGE AND ADMINISTRATION).

Lidocaine has been used occasionally with flecainide while awaiting the therapeutic effect of flecainide. No adverse drug interactions were apparent. However, no studies have been performed to demonstrate the usefulness of this regimen.

**Use in Pregnancy**
Flecainide has been shown to have teratogenic effects (eg, club paws, sternebrae and vertebrae abnormalities, pale hearts with contracted ventricular septum) and an embryotoxic effect (eg, increased resorptions) in one breed of rabbit (New Zealand White) but not in another breed of rabbit (Dutch Belted) when given in doses about four times (but not three times) the usual human dose, assuming a patient weight of 50 kg. No teratogenic effects were observed in rats or mice given doses up to 50 to 80 mg/kg/day, respectively; however, delayed sternebral and vertebral ossification was observed at the high dose in rats. There is no information about the effect on human fetus. Flecainide should not be used during pregnancy unless as a drug of last resort in life-threatening arrhythmias.
**Labor and Delivery**
It is not known whether the use of flecainide during labor or delivery has immediate or delayed adverse effects on the mother or fetus, affects the duration of labor or delivery, or increases the possibility of forceps delivery or other obstetrical intervention.

**PRECAUTIONS**

**Hepatic Impairment**
Since flecainide elimination from plasma can be markedly slower in patients with significant hepatic impairment, flecainide should not be used in such patients unless the potential benefits clearly outweigh the risks. If used, early and frequent plasma level monitoring is required to guide dosage (see DOSAGE AND ADMINISTRATION, Plasma Level Monitoring); dosage increases should be made very cautiously when plasma levels have plateaued (after more than four days).

Abnormalities of liver function have rarely occurred in patients treated with flecainide (see ADVERSE REACTIONS). In foreign post-marketing surveillance studies, there have been rare reports of hepatic dysfunction including reports of cholestasis and hepatic failure. Although no causal relationship has been established, periodic monitoring of liver function tests should be carried out during flecainide therapy. In patients who develop unexplained jaundice or signs of hepatic dysfunction, it is advisable to discontinue flecainide in order to eliminate the drug as the possible causative agent.

**Renal Impairment**
The elimination of flecainide from the body depends on renal function (eg, 10 to 50% appears in urine as unchanged drug). With increasing renal impairment, the extent of unchanged drug excretion in urine is reduced and the plasma half-life of flecainide is prolonged. Different dosage regimens are recommended for patients with various degrees of renal insufficiency (see Pharmacokinetics/Metabolism and DOSAGE AND ADMINISTRATION).

**Blood Dyscrasias**
There have been extremely rare reports of blood dyscrasias (pancytopenia, anemia, thrombocytopenia, leukopenia, granulocytopenia). Although no causal relationship has been established, it is advisable to discontinue flecainide in patients who develop blood dyscrasia in order to eliminate flecainide as the possible causative agent.
**Occupational Hazards**
Since flecainide can cause dizziness, light-headedness, faintness and visual disturbance, patients should be cautioned about engaging in activities requiring judgement and physical coordination (such as driving an automobile or operating dangerous machinery) when these effects occur.

**Elderly Patients**
Flecainide elimination from plasma is somewhat slower in this age group (see DOSAGE AND ADMINISTRATION).

**Nursing Mothers**
Flecainide is excreted in human milk. Because of the drug's potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

**Use in Children**
The safety and effectiveness of flecainide in children below the age of 18 years have not been established.

**Drug Interactions**
Flecainide has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects. During multiple oral doses of flecainide to healthy subjects stabilized on a maintenance dose of digoxin, a 13% to 19% increase in plasma digoxin levels occurred at 6 hours postdose.

In a study involving healthy subjects receiving flecainide and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared with control values. In this study, flecainide and propranolol were each found to have negative inotropic effects; when the drugs were administered together, the effects were additive. The effects of concomitant administration of flecainide and propranolol on the PR interval were less than additive. In flecainide clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects. Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.
Flecainide has been used in a large number of patients receiving diuretics without apparent interaction.

Interactions with antiarrhythmics: See WARNINGS.

Limited data in patients receiving known enzyme inducers (phenytoin, phenobarbital, carbamazepine) indicate a 30% increase in the rate of flecainide elimination.

In healthy subjects receiving cimetidine (1.0 g daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.

Flecainide is not extensively bound to plasma proteins. In vitro studies with several drugs which may be administered concomitantly showed that the extent of flecainide binding to human plasma proteins is either unchanged or only slightly less.

**ADVERSE REACTIONS**

In post-myocardial infarction patients, flecainide was found to be associated with a 5.8% rate of mortality and non-fatal cardiac arrest (see WARNINGS).

Flecainide has been evaluated in 225 patients with supraventricular arrhythmias. The most serious adverse reaction reported for flecainide in patients with supraventricular arrhythmias were new or worsened supraventricular or ventricular arrhythmias which were reported in 4% of patients (see WARNINGS), conduction disturbance which occurred in 2% of patients, and new or worsened congestive heart failure occurred in 0.4% of patients.

The most commonly reported non-cardiac adverse reactions for supraventricular patients remain consistent with those known for patients treated with flecainide for ventricular arrhythmias: vision disturbance 38%, dizziness 37%, headache 18%, nausea 18%, dyspnea 13%, fatigue 13%, chest pain 12%, palpitations 11%. Although these incidences are higher than those reported in ventricular patients it is difficult to compare supraventricular and ventricular data bases because many of the supraventricular patients were dosed to tolerance in the clinical trials.

Flecainide has been evaluated in 1224 patients which included both life threatening and non-life threatening ventricular arrhythmias. The separate figures for these two groups of patients are not
available at this time. The possibility exists that the incidences of adverse reactions in patients with life-threatening ventricular arrhythmias for which this drug is indicated, might be different than that listed below.

The most serious adverse reactions reported for flecainide in patients with ventricular arrhythmias were new or exacerbated ventricular arrhythmias which occurred in 6.8% of patients, and new or worsened congestive heart failure which occurred in 3.9% of patients (or 5.0% of 717 patients in controlled clinical studies). In some patients, flecainide treatment has been associated with episodes of unresuscitatable ventricular tachycardia or ventricular fibrillation. There have also been instances of second- (0.5%) or third-degree (0.4%) AV block. A total of 1.2% of patients developed sinus bradycardia, sinus pause, or sinus arrest (see WARNINGS). The frequency of most of these serious adverse reactions probably increases with higher trough plasma levels, especially when these trough levels exceed 0.7 µg/mL.

The most commonly reported non-cardiac adverse reactions experienced by patients with ventricular arrhythmias participating in clinical trials were dizziness 26.6%, visual disturbance 25.9% (includes blurred vision, diplopia, visual field effects, photophobia), headache 10.4%, nausea 10.1%, and dyspnea 8.6%. Other adverse reactions occurring in over 3% of the patients in clinical trials:

- **Body as a Whole** - fatigue 7.4%, asthenia 4.7%.
- **Cardiovascular** - palpitations 6.0%, chest pain 6.0%.
- **Gastrointestinal** - constipation 4.2%, abdominal pain 3.3%.
- **Nervous System** - tremor 5.6%, nervousness 3.1%, paresthesia 3.1%;
- **Skin** - rash 4.1%.

The following additional adverse reactions, possibly related to flecainide therapy and occurring in 1 to less than 3% of patients have been reported in clinical trials:

- **Body as a Whole** - pain, increased sweating, flushing, dry mouth, arthralgia, fever, myalgia.
- **Cardiovascular** - edema, syncope, tachycardia, angina pectoris, conduction disturbance.
- **Gastrointestinal** - vomiting, diarrhea, anorexia.
- **Nervous System** - hypoesthesia, somnolence, insomnia, ataxia.
- **Respiratory** - coughing.
- **Skin** - pruritus.
- **Special Senses** - tinnitus.
Urinary System - micturition disorder (includes urinary retention, frequency, polyuria, dysuria).

The following additional adverse experiences, possibly related to flecainide, have been reported in less than 1% of patients:

Body as a Whole - impotence, decreased libido, gynecomastia, malaise.
Cardiovascular - bradycardia, EC abnormality, hypertension, hypotension, heart disorder, myocardial infarction, peripheral ischemia, pulmonary edema.
Gastrointestinal - dyspepsia, flatulence, gastrointestinal hemorrhage.
Nervous System - anxiety, twitching, convulsions, nystagmus, stupor, dysphonia, speech disorder, coma, amnesia, confusion, depersonalization, hallucination, paranoid reaction, euphoria, apathy.
Respiratory - bronchospasm, laryngismus.
Skin - dermatitis, hypertrichosis, photosensitivity reaction, skin discoloration.
Special Senses - deafness, parosmia, loss of taste, taste perversion.
Urinary System - renal failure, hematuria.
Laboratory Abnormalities - hyperglycemia, increased nonprotein nitrogen, increased serum alkaline phosphatase, increased serum SGPT and SGOT. Patients with elevations of liver function tests have been asymptomatic and no cause and effect relationship with flecainide has been established.

Adverse reactions leading to discontinuation of therapy occurred in 18.5% of the patients. The two most common were non-cardiac adverse reactions 9.0% and new or worsened arrhythmias 6.8%.

**SYMPTOMS AND TREATMENT OF OVERDOSE**

No specific antidote has been identified for the treatment of flecainide overdose. Animal studies suggest the following events might occur with overdose of flecainide: lengthening of the PR interval; increase in the QRS duration, QT interval and amplitude of the T-wave; a reduction in myocardial rate and contractility; conduction disturbances; hypotension; and death from respiratory failure or asystole. Treatment of overdose should be supportive and may include the following: removal of unabsorbed drug from the gastrointestinal tract, administration of inotropic agents or cardiac stimulants such as dopamine, dobutamine or isoproterenol; mechanically assisted respiration; circulatory assists such as intra-aortic balloon pumping; and transvenous pacing in the event of conduction block. Because of the long plasma half-life of flecainide (range from 12 to 27 hours in patients), and the possibility of markedly nonlinear
elimination kinetics at very high doses, these supportive treatments may need to be continued for extended periods of time.

Hemodialysis is not an effective means of removing flecainide from the body.

Since flecainide elimination is much slower when urine is very alkaline (pH 8 or higher), acidification of urine to promote drug excretion may, theoretically, be beneficial in overdose cases with very alkaline urine. There is no evidence that acidification from normal urinary pH increases excretion.

**DOSAGE AND ADMINISTRATION**

**Supraventricular Arrhythmias**
The recommended starting dose for patients with paroxysmal supraventricular tachycardias or patients with paroxysmal atrial fibrillation/flutter is 50 mg every 12 hrs. FLECAINIDE (Flecainide Acetate) Tablets USP may be increased in increments of 50 mg bid every 4 days until efficacy is achieved. The maximum recommended dose is 300 mg/day.

**Ventricular Arrhythmias**
For patients with sustained ventricular tachycardia, FLECAINIDE (Flecainide Acetate) Tablets USP should be started in the hospital with rhythm monitoring. The recommended starting dose for patients with ventricular arrhythmias is 100 mg every 12 hours. FLECAINIDE may be increased in increments of 50 mg bid every 4 days until efficacy is achieved. Most patients do not require more than 150 mg every 12 hours (300 mg/day). The maximum dose is 400 mg/day.

Use of higher initial doses and more rapid dosage adjustments than recommended has resulted in an increased incidence of proarrhythmic events and CHF, particularly during the first few days of dosing (see WARNINGS). Therefore, a loading dose is not recommended.

An occasional patient not adequately controlled by (or intolerant to) a dose given at 12-hour intervals may be given FLECAINIDE Tablets at 8-hour intervals.
Once adequate control of the arrhythmia has been achieved, it may be possible in some patients to reduce the dose as necessary to minimize side effects or effects on conduction. In such patients, efficacy at the lower dose should be evaluated.

In patients with a history of congestive heart failure (CHF) or myocardial dysfunction, the initial dose should be no more than 100 mg every 12 hours. If needed to achieve efficacy, the dosage may be increased cautiously in increments of 50 mg bid every 4 days, and the maximum dosage should not exceed 200 mg every 12 hours (400 mg/day), because higher doses are associated with a greater incidence of worsened congestive heart failure (see WARNINGS).

**Dosage Adjustment in Renal Impairment**

In patients with severe renal impairment (creatinine clearance of 35 mL/min/1.73 m² or less), the initial dosage should be 50 mg to 100 mg once daily. When used in such patients, daily trough plasma level flecainide monitoring is required to guide dosage adjustments (see Plasma Level Monitoring). In patients with less severe renal disease, the initial dosage should be 100 mg every 12 hours, however, plasma level monitoring is recommended in these patients during dosage adjustment. In both groups of patients, dosage increases should be made very cautiously when plasma levels have plateaued, observing the patient closely for signs of adverse cardiac effects or other toxicity. It should be borne in mind that in these patients it is likely to take longer than 4 days before a new steady state plasma level is reached following a dosage change. Therefore the interval between dose increases should be longer than the 4 days recommended for patients with normal renal function.

**Elderly Patients**

In elderly patients flecainide elimination from plasma is somewhat slower. The initial dosage need not be adjusted, however, daily trough plasma flecainide level monitoring is recommended during dosage adjustment.

**Plasma Level Monitoring**

Therapeutic trough plasma flecainide levels were found to range between 0.2 and 1.0 µg/mL. The probability of adverse experiences, especially cardiac, may increase with higher trough plasma levels, especially when these exceed 0.7 µg/mL. Periodic monitoring of trough plasma levels may be useful in patient management. Because elimination of flecainide from plasma may be markedly slower in patients with severe chronic renal failure or severe hepatic disease, plasma level monitoring is required in these patients. Plasma level monitoring is recommended in patients with congestive heart failure, moderate renal disease, and the elderly.
Based on theoretical considerations, rather than experimental data, the following suggestion is made: when transferring patients from another antiarrhythmic drug to FLECAINIDE or from FLECAINIDE to another antiarrhythmic, allow at least two to four plasma half-lives to elapse for the drug being discontinued before starting the alternative at the usual dosage. In patients where withdrawal of a previous antiarrhythmic agent is likely to produce life-threatening arrhythmias, the physician should consider hospitalizing the patient.

When FLECAINIDE and amiodarone are to be coadministered (see WARNINGS) the dose of FLECAINIDE should be reduced by 50% and the patient should be monitored closely for adverse reactions. Steady-state trough plasma flecainide level monitoring is strongly recommended to guide dosage with such combination therapy.

PHARMACEUTICAL INFORMATION

Drugs Substance
Proper Name: Flecainide Acetate
Chemical Name(s): 1) Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate;

2) N-(2-Piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide monoacetate.

Structural Formula:

Molecular Formula: C_{17}H_{20}F_{6}N_{2}O_{3} \cdot C_{2}H_{4}O_{2}
Molecular Weight: 474.39
Description: Flecainide acetate is a white crystalline substance with a pKa of 9.3. It is soluble in water with an aqueous solubility at 37°C of 48.4 mg/mL.
FLECAINIDE (Flecainide Acetate) Tablets USP contain 50 mg or 100 mg of flecainide acetate per tablet. FLECAINIDE Tablets also contain the following non-medicinal ingredients: croscarmellose sodium, stearic acid, magnesium stearate, colloidal silicon dioxide and methylcellulose.

**STABILITY AND STORAGE CONDITIONS**
Store at room temperature (15°C - 30°C) and protect from light.

**AVAILABILITY OF DOSAGE FORMS**
FLECAINIDE (Flecainide Acetate) Tablets USP are available as follows:

- **50 mg Tablets:** Round, white, biconvex tablets, engraved “FLE” over “50” on one side.
- **100 mg Tablets:** Round, white, biconvex tablets, scored and engraved “FLE” over “100” one side.

FLECAINIDE 50 mg and 100 mg are available in bottles of 100 tablets.

**PHARMACOLOGY**
Flecainide demonstrated antifibrillatory action both orally (23 mg/kg) and parenterally (5.4 mg/kg) in mice exposed to toxic concentrations of chloroform. Atrial and ventricular arrhythmias induced experimentally in dogs by hydrocarbon-epinephrine, ouabain and aconitine administration, as well as those induced by coronary ligation, were suppressed by flecainide at IV doses of 3.4, 1.0, 7.2 and 3.2 mg/kg respectively.

Studies in isolated Purkinje fibers show that flecainide at 1.0 µg/mL decreased upstroke velocity, had no effect on action potential duration and lengthened the effective refractory period. Similar studies in isolated atrial and ventricular muscle fibers showed similar results, except that the duration of the ventricular action potential was increased.

Studies in dogs show that intravenous flecainide, 0.1 to 0.25 mg/kg/min, depressed conduction in all tissues of the heart; this was most pronounced in the His-Purkinje system and in the ventricular muscle. The degree of depression was related to flecainide plasma concentration (0.1 to 10.0 µg/mL). Ventricular fibrillation threshold was increased. Mean aortic blood pressure was not greatly changed.
When tested in isolated guinea pig atria, the concentration of flecainide, lidocaine, and quinidine which produced a 30% decrease in atrial contraction force were determined to be 5.5, 31 and 160 µg/mL, respectively.

Evidence of depressed nerve conduction and/or ganglionic blockade was observed in anesthetized dogs where attenuation of responses to carotid occlusion, right vagal stimulation and cardiac nerve stimulation were demonstrated after 5 mg/kg of intravenous flecainide. These actions were probably due to the local anesthetic effect of flecainide.

Large cumulative intravenous doses (188.0 to 342.0 mg) of flecainide administered to dogs by constant infusion gradually depressed heart rate and blood pressure and finally caused respiratory failure and death.

No apparent vasodilatory activity was observed for flecainide given intra-arterially in doses up to 1.2 mg in the perfused hind limb of the dog at constant blood flow. At 5.0 mg/kg intravenously, flecainide had no apparent effect on regional blood flow in carotid, femoral, renal and superior mesenteric vascular beds.

Local anesthetic action similar to lidocaine was demonstrated for flecainide (0.25 and 0.5% solutions) administered topically to the rabbit cornea. When given intramuscularly, flecainide (0.05 mL of 0.5 to 3.0% aqueous solutions) showed regional nerve block of equal intensity but of longer duration than lidocaine in the mouse sciatic nerve preparations.

**TOXICOLOGY**

**Acute Toxicity**

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>Sex</th>
<th>LD$_{50}$ (mg/kg)</th>
<th>(95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>PO</td>
<td>Male</td>
<td>190</td>
<td>(151-239) mg/kg</td>
</tr>
<tr>
<td>Mouse</td>
<td>IP</td>
<td>Male</td>
<td>79</td>
<td>(72-86) mg/kg</td>
</tr>
<tr>
<td>Mouse</td>
<td>IV</td>
<td>Male</td>
<td>24</td>
<td>(23-25) mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>PO</td>
<td>Male</td>
<td>498</td>
<td>(452-549) mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>PO</td>
<td>Female</td>
<td>567</td>
<td>(422-763) mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>IV</td>
<td>Male</td>
<td>20</td>
<td>(17-23) mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>IV</td>
<td>Female</td>
<td>23</td>
<td>(21-25) mg/kg</td>
</tr>
</tbody>
</table>
Primary signs of acute toxicity were hypoactivity, ataxia, tremors, convulsions, prostration, salivation, emesis, apnea, tachypnea and dyspnea.

*Minimum lethal dose

**Subacute and Chronic Toxicity**

The studies performed are summarized in Table 1. For all studies, animals in each group were equally divided by sex.

<table>
<thead>
<tr>
<th>Species</th>
<th>Route of Dosing</th>
<th>Duration of Dosing</th>
<th>Daily Dose (mg/kg)</th>
<th>No. of Animals per Dose Group</th>
<th>No. of Deaths per Dose Group</th>
<th>Toxic Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>IV</td>
<td>2 weeks</td>
<td>0</td>
<td>20</td>
<td>0</td>
<td>Dose-related ataxis and dyspnea were observed for one to five minutes following dosing at all treatment levels and apnea was observed for 15 to 20 seconds after dosing in the high-dose animals. Four control, three low-, one mid- and two high-dose rats had focal microscopic inflammatory lesions in the lung consisting of perivascular lymphoid accumulations, foci of histio-cytes in alveoli, slightly thickened alveolar walls, and foci of subacute to chronic pneumonia singly or in combination. One low-dose animal had chronic inflammation in the liver.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>20</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>20</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15</td>
<td>20</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>PO</td>
<td>3 months</td>
<td>0</td>
<td>20</td>
<td>0</td>
<td>A significant decrease in body weight was observed in the mid and high-dose groups. Foreign body granulomatous pneumonia occurred in all groups (including controls) and small microscopic foci (infiltration of lymphocytes and macrophages) were found in the myocardium of one control, one low-dose and three mid-dose rats.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20</td>
<td>20</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>80</td>
<td>20</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>160</td>
<td>20</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>PO</td>
<td>3 months</td>
<td>0</td>
<td>20</td>
<td>0</td>
<td>A significant decrease in body weight gain occurred in the high-dose group. A significant increase in relative heart weights occurred in the males of all three treatment groups and in the high-dose females. The high-dose males also had significantly increased relative liver and adrenal weights. A few small microscopic foci of chronic inflammation with fibrosis were found in the heart of one high-dose male.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20</td>
<td>20</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>40</td>
<td>20</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>80</td>
<td>20</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>
ECG changes (sinus tachycardia and 140 prolonged atrial and intraventricular conduction times) were noted in the high-dose group. Mild subacute to chronic pyelonephritis and/or mild chronic interstitial nephritis was present in the kidney of two control, one mid-dose and one high-dose dog.

ECG changes (prolonged atrial and atrioventricular conduction time, alterations in QRS morphology and "peaking" of the T-wave) were noted in the mid and high-dose groups. One mid-dose female had a small (microscopic) focus of mononuclear inflammatory cells in association with a few necrotic myofibrils in the cardiac papillary muscle.

ECG changes (prolongation in the duration of the P wave and the QT interval) were noted in the high-dose group. A group mean body weight loss or failure to gain weight occurred in the mid and high-dose groups during the last six months of the study. The high and mid-dose groups had increased relative heart weights. One dog in the high-dose group had an increased relative pituitary weight caused by a pituitary cyst. Pulmonary subacute focal inflammation was present in the high and mid-dose groups. Several animals in the mid and high-dose groups had some of the following histologic findings: areas of chronic pneumonia, pneumonitis, increased numbers of macrophages (some of which contained hemosiderin) and condensation of alveolar walls with mild emphysema.

In the high-dose group there was a 24% increase in the relative heart weights compared to controls. All treatment groups had a 7-9% increase in relative liver weights compared to controls. Hyperplastic lymphoid follicles in the submucosa of the digestive tract were noted in control and high-dose animals.

---

**Carcinogenesis and Mutagenesis**

Carcinogenicity studies with flecainide in rats and mice at doses up to 60 mg/kg/day did not reveal any carcinogenic effects.
Mutagenicity studies (Ames test, mouse lymphoma and \textit{in vivo} cytogenetics) did not reveal any mutagenic effects.

\textbf{Reproductive Studies}
A rat reproduction study at doses up to 50 mg/kg/day did not reveal any adverse effect on male or female fertility.
No teratogenic effects were found in rats when given flecainide at doses up to 50 mg/kg/day and no teratogenic effects were found in mice when given flecainide at doses up to 80 mg/kg/day. Flecainide has been shown to be teratogenic in one breed of rabbit (New Zealand white). Increased resorption sites were noted at doses of 25, 30 and 35 mg/kg/day. Teratogenic effects (clubbed paws, heart changes, sternebrae and vertebrae abnormalities) were noted at doses of 30 and 35 mg/kg/day. No teratogenic effects were observed in another breed of rabbit (Dutch Belted) at doses up to 30 mg/kg/day.
BIBLIOGRAPHY


